Form 4: Sarepta Therapeutics EVP Ryan Brown Reports Stock Sale to Cover Tax Obligations
SEC Form 4
EVP and General Counsel of Sarepta Therapeutics, Ryan Edward Brown, reports the sale of 1,734 shares of common stock to cover tax obligations related to vesting of restricted stock units.
Summary
- On March 4, 2024, Ryan Edward Brown, EVP and General Counsel of Sarepta Therapeutics, sold 1,734 shares of common stock.
- The sale was executed to satisfy tax withholding obligations related to the vesting of restricted stock units granted on March 3, 2021.
- The price per share was $125.32.
- Following the transaction, Brown directly owns 30,093 shares of Sarepta Therapeutics.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing relates to a routine stock sale for tax purposes and doesn't indicate any fundamental change in the company's prospects.
Industry Context
Form 4 filings are a routine part of executive compensation and provide transparency into insider transactions. This transaction is related to tax obligations, which is a common reason for stock sales by executives.
Stakeholder Impact
- The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| 03/03/2021 | Date of grant for restricted stock units related to the tax obligation. |
| 03/04/2024 | Date of the stock sale transaction. |
| 03/06/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.